News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
It has planned an investment of over Rs 80 crore in the next five years
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Subscribe To Our Newsletter & Stay Updated
